SOCS1
|
Breast cancer |
Up-regulation |
Associated with better clinical outcomes |
[19] |
Down-regulation |
Enhances cell proliferation and colony formation |
[20] |
Colorectal tumor |
Up-regulation |
Reduces tumor cell invasion |
[21] |
Multiple myeloma |
Down-regulation |
Supports the survival and expansion of multiple myeloma cells |
[22] |
Prostate cancer |
Down-regulation |
Associated with regional lymph node invasion |
[23] |
SOCS2
|
Hepatocellular carcinoma |
Down-regulation |
Associated with aggressive tumor progression and poor prognosis |
[15] |
Prostate cancer |
Down-regulation |
Promotes cancer metastasis |
[24] |
SOCS3
|
Prostate cancer |
Down-regulation |
Associated with unfavorable clinical outcome |
[25] |
Colorectal cancer |
Up-regulation |
Inhibits proliferation, migration, and invasion, while increasing cell apoptosis |
[26] |
SOCS4
|
Thyroid cancer |
Down-regulation |
Induces cell migration and invasion |
[27] |
Renal cancer |
Down-regulation |
Promotes cells proliferation and migration |
[28] |
SOCS5
|
Pancreatic cancer |
Down-regulation |
Promotes tumor growth, invasion, and metastasis |
[29] |
Hepatocellular carcinoma |
Down-regulation |
Induces autophagy, reduces cell invasion and metastasis |
[30] |
SOCS6
|
Breast cancer |
Down-regulation |
Promotes cell proliferation, tumor growth and induces tamoxifen resistance |
[31] |
Gastric cancer |
Down-regulation |
Inhibits cell proliferation and colony formation |
[32] |
Hepatocellular carcinoma |
Down-regulation |
Induces aggressive tumor progression and poor prognosis |
[15] |
SOCS7
|
Bladder cancer |
Up-regulation |
Induces tumor growth |
[33] |
Breast cancer |
Down-regulation |
Increases tumor growth and migration |
[34] |
CIS
|
Breast cancer |
Up-regulation |
Increases cell proliferation |
[17] |